Company
LEO Pharma
Copenhagen-founded pharmaceutical company, majority-owned by the LEO Foundation since 1984. Anzupgo (delgocitinib) is its topical JAK-inhibitor cream for chronic hand eczema, already approved for adults in the EU and US.
1 story
Regulatory News has published 1 story about LEO Pharma on 28 September 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 28 September 2026.
This page is generated from Regulatory News’ editorial coverage of LEO Pharma. It is not an advertisement.
On the record
- Company
- LEO Pharma A/S
- Headquarters
- Ballerup, Denmark
- Founded
- 1908, Copenhagen
- Regulator
- European Medicines Agency (CHMP); European Commission decision pending
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
